Tolerance to somatostatin analogue in a preterm infant with islet cell dysregulation syndrome.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 2025013.
- Also identified by PMC identifier 1792864.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An infant of 31 weeks' gestation presented with refractory neonatal hypoglycaemia secondary to islet cell dysregulation. Treatment was started with somatostatin analogue and his glycaemic control improved initially. Tolerance developed, however, in that the dose required to maintain control increased by a factor of 40. The infant subsequently underwent pancreatectomy. It is safe to use somatostatin analogue in a preterm infant, but tolerance to the drug rapidly develops.
Medical subject headings
- Hyperinsulinism
- Hypoglycemia
- Infant, Premature, Diseases
- Octreotide